BRIEF-Health Canada grants priority review to Abbvie's investigational regimen of Glecaprevir
* Health Canada grants priority review to Abbvie's investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of chronic hepatitis c in all major genotypes (GT1-6) Source text for Eikon: Further company coverage: [Source]
Publication Date:Origin: reuters.com
Category: rbssHealthcareNews
Topics: regimen, review, priority, grants, Canada, coverage, company, Further, Eikon, genotypes (GT1-6) Source, major, hepatitis, chronic, treatment, for the, (G/P), Glecaprevir/Pibrentasvir, Abbvie's investigational, Health, Glecaprevir, investigational, Abbvie's, BRIEF-Health
Source: http://feeds.reuters.com/~r/reuters/UShealthcareNews/~3/w7rlesRK3Gc/idUSFWN1FM0QZ